MCF7may

MCF7may is a designation used in some breast cancer research to refer to a subline or variant of the widely used MCF-7 human breast cancer cell line. In the literature, the label often denotes cells that have undergone specific culture conditions, selective pressures, or passaging histories intended to alter certain biological responses, particularly those related to hormone signaling. The exact characteristics attributed to MCF7may can vary between studies, reflecting differences in how the subline was generated and maintained.

Characterization of MCF7may typically emphasizes changes in hormone receptor–mediated biology. Compared with the parental MCF-7 line, MCF7may variants are frequently described as showing modified estrogen receptor signaling, with potential differences in sensitivity to estrogen, anti-estrogen drugs such as tamoxifen, or other endocrine therapies. Gene expression and epigenetic profiles in MCF7may are reported to diverge from those of MCF-7 in ways that may influence proliferation, differentiation, and response to therapeutic agents. However, reported features are not universally consistent across all studies, and the exact mutations, copy-number changes, or receptor status can differ between isolates.

Research applications for MCF7may include studying endocrine therapy resistance, hormone-driven gene regulation, and drug screening in an MCF-7–like context. It is used in vitro under standard cell culture practices, typically in adherent, hormone-responsive conditions, with appropriate biosafety measures. Researchers generally compare MCF7may results with those from the parent MCF-7 line to identify lineage- or condition-specific effects.